Whalesbook
US FDA ki Manzoori Mili!
Concord Biotech ko US FDA se mycophenolate mofetil oral suspension drug ke liye approval mil gaya hai. Yeh ek bada step hai US market mein entry ke liye, jiska size lagbhag $30 million hai. Yeh drug transplant patients ke liye zaroori hai organ rejection control karne mein. Company apni traditional fermentation business ke alawa revenue badhane ki koshish kar rahi hai. Lekin, asal challenge abhi launch karne aur profitable banne mein hai, kyunki US mein generic drugs ke liye competition bahut zyada hai.
Stock Price Udi, Par Numbers Ne Dikha Di Haqiqat
News aate hi stock mein kaafi excitement dikhi aur price 10.01% badh kar ₹1,166.80 ho gaya. Lekin, company ke latest financial results kuch aur hi keh rahe hain. Revenue 24.1% kam hokar ₹326.1 crore ho gaya hai, aur EBITDA margins bhi 44.3% se ghat kar 36.4% ho gaye hain. Iska matlab hai ki company ya toh rates kam kar rahi hai ya phir raw material costs control nahi kar pa rahi. Ye sab current dividend ₹7.55 per share ke liye bhi risk hai.
Bear Case Aur Sector Ka Risk
FDA approval ki wajah se market khush hai, par company ki andaruni kamzori ko nazarandaaz nahi kar sakte. Bade pharma companies ki tarah Concord Biotech ke paas itna strong commercial network nahi hai. Generic immunosuppressant market mein share paana bahut mushkil hoga. Net profit mein ₹88.8 crore ki girawat dikha rahi hai ki company volume decline se kaafi sensitive hai. Agar US launch mein koi delay ya manufacturing issue aata hai, toh aur dikkat ho sakti hai. Fermentation technology par zyada depend hone ki wajah se supply chain issues bhi ho sakte hain.
Aage Kya? (Future Outlook)
Management ne bola hai ki woh apne product portfolio ko expand karenge aur US mein pediatric aur adult transplant market mein entry se future results ko stable karne ki ummeed hai. Lekin, analysts ko doubt hai ki kya yeh naya product company ke purane segments mein ho rahe decline ko cover kar paayega. Ab sabki nazar AGM par hai, jahan discussion regulatory win se zyada company ke growth strategy aur earnings pressure par hogi.